REGULATORY MECHANISMS OF PROSTATE TUMOR PROGRESSION

前列腺的异常情况构成了一个主要的医学问题 美国。前列腺炎、良性肥大(BPH)和恶性 前列腺(帽)的生长将影响大多数男性的生活。 65岁。良性前列腺增生症是一种令人不安的异常生长，幸运的是 很容易被各种选择所对待。前列腺癌，如果检测到 早期是可以治愈的，但转移性疾病可能是致命的，因为没有 目前可用于转移性前列腺癌的根治疗法。在……里面 此外，由于生物的极端异质性 前列腺癌的潜在风险关于治疗前列腺癌的最佳方法存在争议 即使是局部疾病也能进行治疗。没有达成共识， 可行的管理和治疗方法。这反映了我们缺乏 对导致这一光谱的生物决定因素的知识 行为水平能够提供适当的治疗 干预。 奥布莱恩泌尿外科中心的这份提案将把注意力集中在 确定与此相关的细胞表型的变化 疾病从正常到癌前病变再到局限性的进展 癌症到远处播散性癌症。在最初的应用程序中，我们 将重点关注与增长因素相关的编程的三个领域 在恶变表型中。 项目一将检查与酪氨酸激酶相关的变化 生长因子，项目二将检查PKC同工酶的变化 进展中的信号通路，项目三将研究 转铁蛋白受体样前列腺特异性膜抗原PSM和 转铁蛋白受体与前列腺癌的进展。 将确定和招募的这些项目和相关项目 将随着时间的推移提供对生物的了解 CAP的进展和为新的干预措施发展强有力的理论基础 战略。

Abnormal conditions of the prostate constitute a major medical problem in the United States. Prostatitis, Benign enlargement (BPH), and malignant growth of the prostate (CaP) will effect the lives of most men over the age of 65. BPH is a bothersome abnormal growth that fortunately is readily treated by a variety of options. Prostatic cancer, if detected early is curable, but metastatic disease can be fatal as there is no currently available curative therapy for metastatic prostatic cancer. In addition, because of the extreme heterogeneity with regard to biologic potential of prostatic cancer there is debate on the best approach to therapy even with localized disease. There is a lack of consensus and viable approaches to management and therapy. This reflects our lack of knowledge of the biologic determinants responsible for this spectrum of behavior at a level that would provide appropriate therapeutic intervention. This O'Brien Urology Center Proposal will focus its attention on determining changes in the cellular phenotype that is associated with the progression of disease from normal to premalignant lesions to localized cancer to distant disseminated cancer. In this initial application we will focus on three areas related to growth factor associated programming in the malignant transformed phenotype. Project One will examine the alterations in tyrosine kinase associated growth factors, Project Two will examine alterations in PKC isoenzymes signal pathways in progression, and Project Three will examine the transferrin receptor like prostate specific membrane antigen PSM and transferrin receptor in prostatic tumor progression. These projects and related projects which will be identified and recruited to the Center will with time provide an understanding of the biology of progression of CaP and develop strong rationales for new interventional strategies.